Literature DB >> 14529842

Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

M Brandon Parrott1, Kristen E Adams, George T Mercier, Hoyin Mok, Samuel K Campos, Michael A Barry.   

Abstract

Development of cell-targeting vectors is an important focus for gene therapy. While some ligands can be genetically inserted into virus capsid proteins for cell targeting, for many ligands, this approach can disrupt either ligand function or vector function. To address this problem for adenovirus type 5 vectors, the fiber capsid protein was genetically fused to a biotin acceptor peptide (BAP). Adenovirus particles bearing this BAP were metabolically biotinylated during vector production by the endogenous biotin ligase in 293 cells to produce covalently biotinylated virions. The resulting biotinylated vector could be retargeted to new receptors by conjugation to biotinylated antibodies using tetrameric avidin (K(d) = 10(-15) M). The biotinylated vector could also be purified by biotin-reversible binding on monomeric avidin (K(d) = 10(-7) M). Finally, this vector was used as a ligand screening platform for dendritic cells in which a variety of structurally diverse protein, carbohydrate, and nucleic acid ligands were easily added to the vector using the biotin-avidin interaction. This work demonstrates the utility of metabolically biotinylated viruses for ligand screening, vector targeting, and virus purification applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529842     DOI: 10.1016/s1525-0016(03)00213-2

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

1.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

2.  Real-time monitoring of NKCC2 endocytosis by total internal reflection fluorescence (TIRF) microscopy.

Authors:  Ankita Bachhawat Jaykumar; Paulo S Caceres; Ibrahim Sablaban; Bakhos A Tannous; Pablo A Ortiz
Journal:  Am J Physiol Renal Physiol       Date:  2015-11-04

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

4.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

5.  Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting.

Authors:  Debadyuti Ghosh; Michael A Barry
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

7.  Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum.

Authors:  Bhaswati Barat; Anna M Wu
Journal:  Biomol Eng       Date:  2007-02-15

8.  Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors.

Authors:  Zhuo Chen; Hoyin Mok; Stephen C Pflugfelder; De-Quan Li; Michael A Barry
Journal:  Exp Eye Res       Date:  2006-06-21       Impact factor: 3.467

9.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

10.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.